(Total Views: 559)
Posted On: 06/22/2025 7:38:03 AM
Post# of 157400
There he is. Nice!
“In specific aim 1, we will generate and characterize AAV bearing capsids that target T and B cells specifically across both macaques and humans.
https://reporter.nih.gov/project-details/1109...ription“
“In specific aim 1, we will generate and characterize AAV bearing capsids that target T and B cells specifically across both macaques and humans.
https://reporter.nih.gov/project-details/1109...ription“
(5)
(0)
Daniel Rizzo
Federal Whistleblower
Case References
• HHS & SEC Whistleblower: HL-1412396
• DOJ Investigation Report / Whistleblower ID: 20250705-0001
• NIH Case Reference: CS1137565
• DoD Case: 16282
• IC IG / 50 U.S.C. §3033 / ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO
FireGate BioTech | AI Lux Veritas™
Contact FireGate Biotech
https://img1.wsimg.com/blobby/go/05a949a0-169...5_FULL.pdf
Federal Whistleblower
Case References
• HHS & SEC Whistleblower: HL-1412396
• DOJ Investigation Report / Whistleblower ID: 20250705-0001
• NIH Case Reference: CS1137565
• DoD Case: 16282
• IC IG / 50 U.S.C. §3033 / ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO
FireGate BioTech | AI Lux Veritas™
Contact FireGate Biotech
https://img1.wsimg.com/blobby/go/05a949a0-169...5_FULL.pdf
